Streetbeat News

Stock Prices

ACAD

BGS

DELL

ELF

JNJ

LCID

SOFI

SYM

UWMC

Jim Cramer shared his views on several stocks, recommending buying Dell Technologies and SoFi, while advising against B&G Foods, Symbotic, and Lucid Group. He also suggested waiting for a pullback on Johnson & Johnson and UWM Holdings.

Portfolio Pulse from Avi Kapoor

August 27, 2024 | 12:40 pm

SCSC

ScanSource reported Q4 2024 earnings and sales that missed analyst estimates. The company posted an adjusted EPS of $0.80, below the expected $0.93, and sales of $746.113 million, missing the $843.143 million estimate. Sales decreased by 21.23% compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 27, 2024 | 12:35 pm

LCID

RIVN

Rivian Automotive Inc. (RIVN) and Lucid Group Inc. (LCID) are two California-based EV startups investing heavily in R&D while yet to turn a profit. Rivian, with higher sales volume, reported a larger net loss compared to Lucid. Both companies are planning new models to expand their market reach. Rivian aims for profitability by late 2024, while Lucid has not provided a timeline. Year-to-date, Lucid's stock is up 2.7%, while Rivian's is down 32%.

Portfolio Pulse from Anan Ashraf

August 27, 2024 | 12:35 pm

HAIN

Hain Celestial Group's Q4 EPS exceeded expectations, leading to an 8.20% premarket stock surge. Despite missing revenue estimates and a decline in net sales, the company forecasts stable or improved organic net sales and gross margin growth for FY25.

Portfolio Pulse from Nabaparna Bhattacharya

August 27, 2024 | 12:34 pm

DCTH

Delcath Systems published a study in the Annals of Surgical Oncology showing that their HEPZATO KIT offers improved survival outcomes for metastatic uveal melanoma patients compared to other therapies. The study highlights better overall survival and progression-free survival rates when used as both first-line and second-line therapy.

Portfolio Pulse from Benzinga Newsdesk

August 27, 2024 | 12:34 pm

BUSE

The trading halt status was updated at 8:25 AM ET, indicating a quotation resumption. This update is crucial for investors tracking the affected stocks.

Portfolio Pulse from Benzinga Newsdesk

August 27, 2024 | 12:25 pm

HUMA

Humacyte, Inc. presented positive long-term results for its acellular tissue engineered vessel (ATEV) used in treating vascular injuries in a military setting. The study showed a 12-month patency rate of 87.1% with no infections, amputations, or deaths, highlighting the potential of ATEV in severe wartime injuries.

Portfolio Pulse from Benzinga Newsdesk

August 27, 2024 | 12:16 pm

AAMC

Altisource Asset Management Corp (AAMC) shares dropped 43.6% after announcing plans to voluntarily delist from the NYSE American due to non-compliance with listing standards and to save costs. The delisting is expected to take effect by September 16.

Portfolio Pulse from Henry Khederian

August 27, 2024 | 12:14 pm

CNTA

Centessa Pharmaceuticals announced that its preclinical data for ORX142, a drug targeting excessive daytime sleepiness, will be presented at Sleep Europe 2024. The data shows promising results in non-human primates.

Portfolio Pulse from Benzinga Newsdesk

August 27, 2024 | 12:13 pm

LLY

Eli Lilly has introduced cheaper vials of its weight-loss drug Zepbound, priced up to 50% lower than other incretin medicines, to increase accessibility. The vials are available for self-pay patients with a valid prescription, expanding supply in response to high demand.

Portfolio Pulse from Vandana Singh

August 27, 2024 | 12:13 pm